Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

ARET2121, Intravitreal Melphalan for Intraocular Retinoblastoma

Primary Investigator
Sedig, Laura
Status
OPEN TO ACCRUAL
Phase
II
NCT Number
NCT05504291
UM Number
2022.121
Age Group
Children
Management Group
CTSU - Oncology
Oncology Group
Childhood Cancers
ID (Protocol)
44296
Secondary Protocol No
HUM00225914
Scope
National
Sponsor Type
Institutional
Disease Site
Eye and Orbit
Summary
This phase II trial tests the safety and side effects of adding melphalan (by injecting it into the eye) to standard chemotherapy in early treatment of patients with retinoblastoma (RB). RB is a type of cancer that forms in the tissues of the retina (the light-sensitive layers of nerve tissue at the back of the eye). It may be hereditary or nonhereditary (sporadic). RB is considered harder to treat (higher risk) when there are vitreous seeds present. Vitreous seeds are RB tumors in the jelly-like fluid of the eye (called the vitreous humor). The term, risk, refers to the chance of the cancer not responding to treatment or coming back after treatment. Melphalan is in a class of medications called alkylating agents. It may kill cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Other chemotherapy drugs given during this trial include carboplatin, vincristine, and etoposide. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Adding melphalan to standard chemotherapy early in treatment may improve the ability to treat vitreous seeds and may be better than standard chemotherapy alone in treating retinoblastoma.

Eligibility: Inclusion Criteria
  •   Patient must be 18 years of age at enrollment
  •   Patient must have newly diagnosed intraocular (localized) retinoblastoma and meet one of the following criteria:
  •   Unilateral Group D retinoblastoma with vitreous seeding; OR
  •   Bilateral retinoblastoma with worst eye Group D, with vitreous seeding present and the contralateral eye is Group A-C; OR
  •   Bilateral retinoblastoma with one Group D eye with vitreous seeding and one Group E eye where the Group E eye has been enucleated prior to any therapy. Note exclusion for high-risk features
  •   Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =16 years of age
  •   Peripheral absolute neutrophil count (ANC) >= 750/uL (must be performed within 7 days prior to enrollment unless otherwise indicated)
  •   Platelet count >= 75,000/uL (transfusion independent) (must be performed within 7 days prior to enrollment)
  •   A serum creatinine based on age/gender as follows (must be performed within 7 days prior to enrollment; must be repeated prior to the start of protocol therapy if > 7 days have elapsed from their most recent prior assessment):
  •   1 month to 6 months = 0.4 (male and female)
  •   6 months to 1 year = 0.5 (male and female)
  •   1 to 2 years = 0.6 (male and female)
  •   2 to 6 years = 0.8 (male and female)
  •   6 to 10 years = 1.0 (male and female)
  •   10 to 13 years = 1.2 (male and female)
  •   13 to 16 years = 1.5 (male) and 1.4 (female)
  •   >= 16 years = 1.7 (male) and 1.4 (female) OR - a 24-hour urine Creatinine clearance >= 70 mL/min/1.73 m^2 OR - a glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
  •   Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  •   For patients 1 month of age, serum creatinine levels must be 1.5 x the treating institution's creatinine upper limit of normal (ULN) for patients 1 month of age or the creatinine clearance or radioisotope GFR must be >= 70 mL/min/1.73 m^2
  •   Total bilirubin = 1.5 x upper limit of normal (ULN) for age (must be performed within 7 days prior to enrollment; must be repeated prior to the start of protocol therapy if > 7 days have elapsed from their most recent prior assessment)
  •   Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) = 135 U/L (must be performed within 7 days prior to enrollment; must be repeated prior to the start of protocol therapy if > 7 days have elapsed from their most recent prior assessment)
  •   Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
Exclusion Criteria
  •   Patients with evidence of metastatic or extra-orbital spread
  •   Patients must not have an invasive infection at time of protocol entry
  •   Patients must not have had any prior anti-cancer therapy to the study eye(s), including focal, local, or systemic chemotherapy or radiation therapy
  •   Note: A study eye is defined as being Group D with vitreous seeding. Patients may have had enucleation of one eye as long as the remaining eye is Group D with vitreous seeds
  •   Patients with no reasonable expectation for any useful vision in the Group D eye as determined by the treating physician
  •   Patients with bilateral disease who undergo enucleation of a Group E eye prior to initiation of therapy and show evidence of high-risk histopathology features in the enucleated eye. High-risk histopathology includes choroid involvement >= 3 mm, post lamina optic nerve involvement, full thickness scleral invasion or optic nerve invasion to the cut end
  •   Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
  •   Lactating females who plan to breastfeed their infants
  •   Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
  •   All patients and/or their parents or legal guardians must sign a written informed consent
  •   All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met